Olr1433 inhibitors are a class of chemical compounds designed to target and modulate the activity of the Olr1433 receptor, a protein encoded by the Olr1433 gene. The Olr1433 receptor belongs to the family of G-protein coupled receptors (GPCRs), which play crucial roles in cellular signaling by responding to various extracellular stimuli. Inhibitors of Olr1433 are structurally diverse, often comprising small molecules that bind to the receptor's active site or allosteric sites, thereby preventing its natural ligands from activating the receptor. The inhibition of Olr1433 can alter downstream signaling pathways, impacting various cellular processes depending on the tissue or cell type in which the receptor is expressed.
The chemical design of Olr1433 inhibitors involves optimizing the binding affinity, selectivity, and stability of the compounds to ensure effective receptor modulation. Structural analyses, including X-ray crystallography and molecular modeling, are often employed to identify key interactions between the inhibitors and the Olr1433 receptor. These studies guide the refinement of chemical scaffolds to enhance specificity and reduce off-target effects. Additionally, various chemical techniques, such as high-throughput screening and structure-activity relationship (SAR) studies, are utilized to identify lead compounds and optimize their inhibitory potency. Understanding the chemical properties of Olr1433 inhibitors, such as their lipophilicity, solubility, and metabolic stability, is essential for advancing the development of these compounds. This class of inhibitors represents a significant area of interest in chemical research, particularly in elucidating the biological functions of the Olr1433 receptor and its role in various cellular contexts.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic antagonist, could modulate GPCR activity, indirectly affecting Olr1433. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $122.00 $235.00 $520.00 $979.00 $1500.00 | 2 | |
Beta-adrenergic antagonist with alpha-1 blocking, might influence Olr1433 signaling pathways. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $50.00 $168.00 $520.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, could affect GPCR signaling pathways related to Olr1433. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $176.00 | ||
Combined alpha/beta blocker, might indirectly affect GPCR pathways including Olr1433. | ||||||
Pindolol | 13523-86-9 | sc-204847 sc-204847A | 100 mg 1 g | $194.00 $760.00 | ||
Beta-adrenergic antagonist, may influence GPCR-mediated signaling pathways related to Olr1433. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Beta-adrenergic agonist, might indirectly affect Olr1433 through GPCR modulation. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $200.00 | 2 | |
Muscarinic acetylcholine receptor antagonist, may influence GPCR signaling pathways including Olr1433. | ||||||
Salmeterol | 89365-50-4 | sc-224277 sc-224277A | 10 mg 50 mg | $186.00 $562.00 | 1 | |
Beta-2 adrenergic agonist, potentially affecting GPCR pathways related to Olr1433. | ||||||
Alprenolol | 13655-52-2 | sc-507469 | 50 mg | $130.00 | ||
Beta blocker, could indirectly influence GPCR signaling pathways including Olr1433. |